Home › Newsroom › Jayapal Proposes Mandatory Public Charters for AI ...
Newsroom

Jayapal Proposes Mandatory Public Charters for AI Companies

Jayapal Proposes Mandatory Public Charters for AI Companies

Representative Pramila Jayapal unveiled legislation on Thursday that would force every artificial intelligence firm operating in the United States to secure a public charter. The proposal seeks to mirror the regulatory framework used for the banking sector, requiring companies to meet strict public benefit obligations to retain their operating license.

The Washington Democrat argues that current piecemeal regulations are insufficient to counter the influence of major technology firms. Under the proposed system, the government would exert direct control over the AI safety review process. This would include mandatory testing in federal facilities, adversarial stress tests, and a government-controlled kill switch for non-compliant systems. Jayapal described the move as a necessary response to firms that have built massive empires by leveraging mass surveillance and personal data.

Beyond basic oversight, the bill targets specific industry practices like surveillance pricing, where firms use consumer data to adjust individual costs. The legislation introduces severe liability for harmful AI actions, culminating in the potential revocation of a company’s charter—a penalty Jayapal characterizes as a corporate death sentence. While the bill faces stiff opposition from President Donald Trump and House Speaker Mike Johnson, it serves as a central pillar of the Democratic platform heading into the November midterm elections.

Proponents, including former Federal Trade Commission Chair Lina Khan, contend that the public has paid an excessive price for industry self-regulation. Sacha Haworth of the Tech Oversight Project echoed this sentiment, arguing that the framework establishes essential rules of the road to hold unaccountable monopolies in check. The proposal signals a shift toward treating AI providers with the same rigorous scrutiny currently applied to nuclear operators and drug manufacturers.

Share:TelegramXFacebook

Read Also

Comments (0)

Leave a comment

No comments yet. Be the first!